intermediate/high-risk non-muscle-invasive bladder cancer
Conditions
Interventions
control group:Standard cystoscopy follow-up every 3 months for 2 years
intervention group:UROCAD-guided follow-up
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years; 2. Pathologically confirmed intermediate- or high-risk NMIBC (including T1, CIS, high-grade Ta, multiple, or recurrent tumors); 3. Completed TURBT and immediate intravesical instillation therapy; 4. No imaging evidence indicating upper urinary tract tumors or distant metastasis within 3 months postoperatively; 5. ECOG performance status of 0-2; 6. Expected to complete the 24-month follow-up; 7. Voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Previous or concurrent presence of muscle-invasive bladder cancer, upper tract urothelial carcinoma, or other malignant tumors; 2. Presence of macroscopic residual tumor after surgery; 3. Severe cardiac, hepatic, or renal dysfunction; 4. Immunodeficiency or long-term use of immunosuppressants; 5. Pregnant or lactating women; 6. Recent participation in other clinical trials; 7. Other conditions considered unsuitable for participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year high-grade recurrence-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2 years of progression-free survival;2-year recurrence-free survival;Number of cystoscopy examinations; | — |
Countries
China
Contacts
Public ContactChuanliang Xu
Zhejiang Cancer Hospital
Outcome results
None listed